Vincerx Pharma (VINC) Short Interest Ratio & Short Volume → Shocking: One AI startup's revenue could surge 4,735% (From Manward Press) (Ad) Free VINC Stock Alerts $0.80 -0.05 (-5.87%) (As of 05/10/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Vincerx Pharma Short Interest DataCurrent Short Volume1,030,000 sharesPrevious Short Volume1,200,000 sharesChange Vs. Previous Month-14.17%Dollar Volume Sold Short$851,810.00Short Interest Ratio / Days to Cover0.9Last Record DateApril 30, 2024Outstanding Shares21,410,000 sharesFloat Size17,220,000 sharesShort Percent of Float5.98%Today's Trading Volume434,432 sharesAverage Trading Volume542,237 sharesToday's Volume Vs. Average80% Short Selling Vincerx Pharma ? Sign up to receive the latest short interest report for Vincerx Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatVINC Short Interest Over TimeVINC Days to Cover Over TimeVINC Percentage of Float Shorted Over Time Ad Stansberry ResearchGold ManiaFormer Goldman VP Reveals Mysterious "Gold Bank" With Huge Upside Potential He says the gains in this should be far greater than just bullion or mining stocks. Some folks had the chance to see 995% the last time we shared this exact "bank". Most people know nothing about it (except the rich and elite).See his free reveal right here. Vincerx Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20241,030,000 shares $851,810.00 -14.2%6.0%0.9 $0.83 4/15/20241,200,000 shares $1.04 million +50.0%8.9%1.1 $0.87 3/31/2024799,900 shares $4.05 million -7.4%5.9%0.6 $5.06 3/15/2024863,700 shares $4.82 million +95.2%6.4%0.8 $5.58 2/29/2024442,400 shares $1.66 million +83.3%3.3%0.5 $3.75 2/15/2024241,400 shares $415,208.00 -29.9%1.8%0.3 $1.72 Get the Latest News and Ratings for VINC and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter. 1/31/2024344,200 shares $450,902.00 -32.8%2.6%0.7 $1.31 1/15/2024512,500 shares $702,125.00 +375.9%3.8%1.1 $1.37 12/31/2023107,700 shares $127,086.00 -12.6%0.8%0.2 $1.18 12/15/2023123,200 shares $77,739.20 -20.1%0.9%1.8 $0.63 11/30/2023154,200 shares $100,230.00 +19.8%1.2%3 $0.65 11/15/2023128,700 shares $99,871.20 -1.3%1.0%2.4 $0.78 10/31/2023130,400 shares $120,567.84 -10.6%1.0%1.6 $0.92 10/15/2023145,800 shares $141,426.00 -13.7%1.1%1.2 $0.97 9/30/2023168,900 shares $170,589.00 -3.7%1.3%1.4 $1.01 9/15/2023175,400 shares $154,352.00 -11.8%1.3%1.3 $0.88 8/31/2023198,900 shares $131,274.00 +87.8%1.5%1.5 $0.66 8/15/2023105,900 shares $91,074.00 -18.5%0.8%0.8 $0.86 7/31/2023129,900 shares $140,292.00 +8.3%1.0%1.2 $1.08 7/15/2023120,000 shares $150,000.00 -76.7%0.9%1.3 $1.25 6/30/2023514,100 shares $668,330.00 -18.6%4.0%5.8 $1.30 6/15/2023631,300 shares $965,889.00 +5.4%4.9%8.1 $1.53 5/31/2023599,200 shares $1.11 million -3.1%4.6%8.5 $1.85 5/15/2023618,300 shares $989,280.00 +1.9%4.4%10.3 $1.60 4/30/2023607,000 shares $795,170.00 +3.7%4.3%10.5 $1.31 4/15/2023585,200 shares $575,134.56 +0.7%4.1%10 $0.98 3/31/2023581,100 shares $604,344.00 +0.6%4.1%10.1 $1.04 3/15/2023577,700 shares $549,392.70 -0.4%3.5%7.9 $0.95 2/28/2023580,000 shares $672,800.00 +0.8%3.6%3 $1.16 2/15/2023575,500 shares $673,335.00 -1.2%3.6%2.8 $1.17 1/31/2023582,300 shares $879,273.00 -1.6%3.6%2.5 $1.51 1/15/2023591,900 shares $627,414.00 -12.8%3.6%2.6 $1.06 12/30/2022678,700 shares $692,274.00 -31.4%4.2%2.8 $1.02 12/15/2022989,200 shares $797,493.04 +59.4%6.1%4.1 $0.81 11/30/2022620,500 shares $434,350.00 -6.5%3.8%5.1 $0.70 11/15/2022663,900 shares $542,273.52 +0.6%4.1%6 $0.82 10/31/2022660,100 shares $706,307.00 +6.2%4.0%6.2 $1.07 10/15/2022621,700 shares $714,955.00 -60.4%3.8%6.1 $1.15 9/30/20221,570,000 shares $2.17 million +2.6%9.6%18 $1.38 9/15/20221,530,000 shares $2.20 million No Change9.3%10.6 $1.44Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. VINC Short Interest - Frequently Asked Questions What is Vincerx Pharma's current short interest? Short interest is the volume of Vincerx Pharma shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 1,030,000 shares of VINC short. 5.98% of Vincerx Pharma's shares are currently sold short. Learn More on Vincerx Pharma's current short interest. What is a good short interest ratio for Vincerx Pharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VINC shares currently have a short interest ratio of 1.0. Learn More on Vincerx Pharma's short interest ratio. What is a good short interest percentage for Vincerx Pharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.98% of Vincerx Pharma's floating shares are currently sold short. Is Vincerx Pharma's short interest increasing or decreasing? Vincerx Pharma saw a decrease in short interest during the month of April. As of April 30th, there was short interest totaling 1,030,000 shares, a decrease of 14.2% from the previous total of 1,200,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Vincerx Pharma's float size? Vincerx Pharma currently has issued a total of 21,410,000 shares. Some of Vincerx Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Vincerx Pharma currently has a public float of 17,220,000 shares. How does Vincerx Pharma's short interest compare to its competitors? 5.98% of Vincerx Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Vincerx Pharma: Indaptus Therapeutics, Inc. (0.44%), Minerva Neurosciences, Inc. (0.47%), NeuroSense Therapeutics Ltd. (0.16%), VBI Vaccines Inc. (1.38%), Aytu BioPharma, Inc. (7.15%), Talphera, Inc. (0.90%), Orgenesis Inc. (0.84%), Vaxxinity, Inc. (3.61%), Aptorum Group Limited (0.50%), Tonix Pharmaceuticals Holding Corp. (1.89%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Vincerx Pharma stock? Short selling VINC is an investing strategy that aims to generate trading profit from Vincerx Pharma as its price is falling. VINC shares are trading down $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Vincerx Pharma? A short squeeze for Vincerx Pharma occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of VINC, which in turn drives the price of the stock up even further. How often is Vincerx Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including VINC, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Indaptus Therapeutics Short Squeeze Minerva Neurosciences Short Squeeze NeuroSense Therapeutics Short Squeeze VBI Vaccines Short Squeeze Aytu BioPharma Short Squeeze Talphera Short Squeeze Orgenesis Short Squeeze Vaxxinity Short Squeeze Aptorum Group Short Squeeze Tonix Pharmaceuticals Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:VINC) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsYou need to know these two things about AI stocks ASAP…InvestorPlaceGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchMissed NVDA? Buy this AI stock NOWChaikin AnalyticsShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill Publishing